Tracon Pharmaceuticals, Inc., a biopharmaceutical company, has filed Post-Effective Amendments to deregister securities associated with its equity incentive and employee stock purchase plans. The amendments affect multiple registration statements on Form S-8, which had previously registered shares of the company's common stock for these plans. The share numbers have been adjusted to reflect two reverse stock splits, one on November 7, 2019, and another on April 10, 2024. This action follows the board of directors' approval of the company's dissolution and liquidation, pending stockholder approval, as disclosed in a Form 8-K filed on July 30, 2024. The filings were made with the U.S. Securities and Exchange Commission on October 31, 2024, and are intended to terminate the offerings and remove any unsold securities from registration.

Tracon Pharmaceuticals, Inc., a biopharmaceutical company, has filed Post-Effective Amendments to deregister securities associated with its equity incentive and employee stock purchase plans. The amendments affect multiple registration statements on Form S-8, which had previously registered shares of the company's common stock for these plans. The share numbers have been adjusted to reflect two reverse stock splits, one on November 7, 2019, and another on April 10, 2024. This action follows the board of directors' approval of the company's dissolution and liquidation, pending stockholder approval, as disclosed in a Form 8-K filed on July 30, 2024. The filings were made with the U.S. Securities and Exchange Commission on October 31, 2024, and are intended to terminate the offerings and remove any unsold securities from registration.